Report overview available upon request. Please contact sales@ls-intel.com.
Abbott Laboratories (St. Jude Medical)
Aleva Neurotherapeutics
Alfred Mann Foundation
Atrotech Oy
Autonomic Technologies
Avery Biomedical
Axonics Modulation Technologies
BioControl Medical
BioElectronics Corporation
Bioinduction/Finetech Medical
Bioness
Bionic Enterprises
BlueWind Medical
Boston Scientific Corporation
BrainsWay
Burke Medical Research Institute
Cala Health
Cardionomic
Cephaly Technology (STX-Med)
Cerbomed GmbH
CerebralRx
Clinatec
Cogentix Medical
CorTec/Wyss Center
CVRx
Deep Brain Innovations
Defense Advanced Research Projects Agency
electroCore
Endonovo Therapeutics
EndoStim
eNeura
Enopace Medical
Feinstein Institute for Medical Research (Northwell Health)
FemPulse LLC
Functional Neuromodulation
Galvani Bioelectronics
Hanger
Hobart Group (Lavita, MetaCure, Renal Dynamics, Impulse Dynamics)
Innovative Health Solutions
Inspire Medical Systems
IntraPace
Laboratoire MXM (Axonic Neuromodulation Systems)
LivaNova (Cyberonics, ImThera)
MagVenture
Mainstay Medical
Medtronic
Micro Transponder
Neurolief
NeuroMetrix
Neuronetics
Neuronix
NeuroPace
NeuroSigmaNeuros Medical
NeuroTech International Ltd./AAT Research Ltd.
NeuroTronik
Nevro
Nexeon Medsystems/Nuviant Medical
Nuvectra
Ottobock
(Beijing) PINS Medical
ReShape Lifesciences (EnteroMedics)
Respicardia
Saluda Medical
Sanguistat
SceneRay
Scion NeuroStim
SetPoint Medical
SPR Therapeutics
Stimwave
Synapse Biomedical
Tal Medical
CHUs Jean Monnet &Saint Etienne/Life Medical Control/NBA Techno
University of California Berkeley
EXECUTIVE SUMMARY
Markets by Clinical Application
Markets by Geography
Suppliers
Summary Exhibit 1: Global Markets by Approach and Clinical Application, 2016-2022
Summary Exhibit 2: Global Market for Neurostimulation Technologies by Major Geography, 2016-2022
Summary Exhibit 3: Global Biomedical Electronic and Neurostimulation Devices Market, Estimated Supplier Shares, 2017
1.0 BACKGROUND ON BIOELECTRONIC MEDICINE & NEUROSTIMULATION
1.1 The Beginning: Cardiac Rhythm Management
1.1.1 Pacemakers: Overwriting Abnormal Electrical Activity of the Heart
1.1.2 High Power CRM Devices
1.1.3 External CRM Devices: Saving Lives Outside of Hospitals
1.1.4 Arrhythmia Ablation: Isolating Parasitic Conduction Pathways
1.2 Expanding Technologies & Applications: Neuromodulation
1.2.1 Spinal Cord Stimulation
1.2.2 Deep Brain Stimulation
1.2.3 Sacral Nerve Modulation
1.2.4 Vagus Nerve Stimulation
1.2.5 New and Emerging Neurostimulation Targets
Exhibit 1-1: Overview of Cardiac Rhythm Management (CRM) Products
Exhibit 1-2 Overview of Selected Neurostimulation Technologies and Applications
2.0 VAGUS NERVE AND NATIVE HOMEOSTASIS MECHANISM
2.1 Overview of Native Homeostasis Mechanism
2.1.1 Parameters Monitored
2.1.1.1 Core Temperature
2.1.1.2 Blood Glucose
2.1.1.3 Blood Calcium, Sodium, Potassium and Iron
2.1.1.4 Blood Oxygen, CO2 Saturation, pH
2.1.1.5 Arterial Blood Pressure, Heart Rate, Respiration
2.1.2 Homeostatic Failures
2.2 Main Components of Homeostasis Mechanism
2.2.1 Cell Signaling
2.2.1.1 Neurotransmitters
2.2.1.2 Cell Receptors
2.2.2 Endocrinal Signaling Features
2.2.2.1 Hormones
2.2.2.2 Cytokines and Other Components
2.3 Vagus Nerve Functional Anatomy and Role in Homeostasis Processes
2.3.1 Functional Anatomy
2.3.2 Role in Homeostasis Process
2.4 Challenges and Limitations
Exhibit 2-1: Schematic of Basic Native Homeostasis System
Exhibit 2-2: Key Parameters Monitored by Homeostasis Mechanism
Exhibit 2-3: Major Components of Homeostasis Mechanism
Exhibit 2-4: Anatomy of a Neuron
Exhibit 2-5: Schematic of Signaling Process
Exhibit 2-6: Components, Functions, and Peripheral Distribution of Vagus Nerve Fibers
3.0 NEUROSTIMULATION TARGETED CLINICAL APPLICATIONS
3.1 Inflammatory Conditions
3.1.1 Rheumatoid Arthritis
3.1.2 Inflammatory Bowel Disease
3.1.3 Multiple Sclerosis
3.2 Neurological Diseases
3.2.1 Refractory Epilepsy
3.2.2 Cluster Headaches
3.2.3 Migraine
3.2.4 Chronic Depression
3.2.5 Post-Traumatic Stress Disorder
3.2.6 Ischemic Stroke
3.2.7 Neurodegenerative Disorders
3.2.7.1 Parkinson's Disease
3.2.7.2 Essential Tremor
3.2.7.3 Alzheimers
3.2.7.4 Amyotrophic Lateral Sclerosis (ALS)
3.3 Hematologic Conditions
3.3.1 Postpartum Hemorrhage
3.3.2 Hemophilia
3.4 Metabolic Conditions
3.4.1 Obesity
3.4.2 Type 2 Diabetes
3.5 Cardiology Conditions: Heart Failure
3.6 Sleep Apnea
3.6.1 Obstructive Sleep Apnea (OSA)
3.6.1 Central Sleep Apnea (CSA)
3.7 Urological Conditions
3.7.1 Urinary Incontinence
3.7.2 Overactive Bladder (OAB)
3.8 Other Targeted Applications
Exhibit 3-1: Overview of Selected Inflammatory Conditions Potentially Amenable to VNS Therapy
Exhibit 3-2: Incidence of Inflammatory Bowel Disease for Selected Nations
Exhibit 3-3 : Prevalence of Inflammatory Bowel Disease by Geography, 2015
Exhibit 3-4: Global Distribution of Multiple Sclerosis, 2017
Exhibit 3-5: Overview of Selected Neurological Conditions Potentially Amenable to Neurostimulation Therapy
Exhibit 3-6: Distribution of Depression by Geography, Age and Sex, 2015
Exhibit 3-7: Current and Forecast Prevalence of Alzheimer's, 2015-2050
Exhibit 3-8: Growth in Prevalence of Amyotrophic Lateral Sclerosis, 2015 – 2040
Exhibit 3-9: Overview of Selected Hematologic Conditions Potentially Amenable to Neurostimulation Therapy
Exhibit 3-10: Overview of Selected Metabolic Conditions Potentially Amenable to Neurostimulation Therapy
Exhibit 3-11: Adult Obesity as Share of Population, 2012 or Most Recent Year
Exhibit 3-12: Global Population 20-79 with Diabetes, 2017 and 2045
Exhibit 3-13: Overview of Heart Failure
Exhibit 3-14: Overview of Sleep Apnea Potentially Amenable to Neurostimulation Therapy
Exhibit 3-15: Overview of Urological Conditions Potentially Amenable to Neurostimulation Therapy
Exhibit 3-16: Other Clinical Applications Potentially Amenable to Neurostimulation Therapy
4.0 PRODUCTS AND TECHNOLOGIES
4.1 Neurological Conditions
4.1.1 Drug Refractory Epilepsy
4.1.1.1 Bionic Enterprises
4.1.1.2 Cerbomed
4.1.1.3 CerebralRX
4.1.1.4 LivaNova
4.1.1.5 NeuroPace
4.1.1.6 NeuroSigma
4.1.1.7 PINS Medical
4.1.2 Drug Resistant Depression
4.1.2.1 BrainsWay
4.1.2.2 Cerbomed
4.1.2.3 CerebralRx
4.1.2.4 Endonova Therapeutics
4.1.2.5 LivaNova
4.1.2.6 MagVenture
4.1.2.7 Neuronetics
4.1.2.8 Tal Medical
4.1.3 Migraine/Cluster Headache
4.1.3.1 Automomic Technologies
4.1.3.2 Cephaly Technology
4.1.3.3 Cerbomed
4.1.3.4 electroCore
4.1.3.5 eNeura
4.1.3.6 Scion NeuroStim
4.1.4 Neurodegenerative Disorders
4.1.4.1 Aleva Neurotherapeutics
4.1.4.2 Bioinduction
4.1.4.3 Functional Neuromodulation
4.1.4.4 Neuronix
4.1.5 Stroke, Spinal Cord Injury and Limb Loss
4.1.5.1 Bioness
4.1.5.2 Finetech Medical
4.1.5.3 Hanger
4.1.5.4 MicroTransponder
4.1.5.5 Ottobock
4.1.5.6 Massachusetts General Hospital
4.1.5.7 Sheffield Teaching Hospital
4.2 Chronic Pain (ex Headache)
4.2.1 BioElectronic Corporation
4.2.2 BlueWind Medical
4.2.3 Cerbomed
4.2.4 Mainstay Medical
4.2.5 NeuroMetrix
4.2.6 Nevro
4.2.7 Saluda Medical
4.2.8 SPR Therapeutics
4.2.9 Stimwave
4.3 Autoimmune Inflammatory Conditions (SetPoint Medical)
4.3.1 Rheumatoid Arthritis
4.3.2 Crohn's Disease
4.4 Hematologic Disorders (Sanguistat)
4.5 Metabolic Disorders: Obesity
4.5.1 University of Saint Etienne Medical Center
4.5.2 Federal University of São Paulo
4.6 Cardiovascular Disorders: Heart Failure
4.6.1 BioControl Medical
4.6.2 Cardionomic
4.6.3 CVRx
4.6.4 Enopace Medical
4.6.5 Impulse Dynamics
4.6.6 LivaNova
4.6.7 Oklahoma State University Health Sciences Center
4.7 Urologic Disorders
4.7.1 Axonics Modulation Technologies
4.7.2 BlueWind Medical
4.7.3 Cogentix Medical
4.7.4 FemPulse LLC
4.8 Sleep Disorders
4.8.1 Inspire Medical
4.8.2 LivaNova/ImThera Medical
4.8.3 Respicardia
4.9 Hearing Disorders: Chronic Tinnitus
4.9.1 CorTec/Wyss Center
4.9.2 MicroTransponder
4.10 Gastrointestinal Disorders: GERD
4.11 Breathing Disorders: Respiratory Insufficiency
4.12 Opioid Withdrawal Symptoms
4.13 Autism
Exhibit 4-1: Current & Emerging Bioelectronic Medicine and Neurostimulation By Clinical Application
5.0 MARKETS BY APPROACH AND CLINICAL APPLICATION
5.1 Neurological Disorders
5.1.1 Parkinson's/Essential Tremor/Alzheimer's (Deep Brain Stimulation)
5.1.2 Drug-Refractory Epilepsy
5.1.3 Major Depressive Disorder
5.1.4 Migraine/Cluster Headache
5.1.5 Post-Stroke Mobility
5.2 Hematologic Disorders (Post-Partum Hemorrhage)
5.3 AutoImmune Inflammatory Disorders
5.4 Chronic Widespread Pain
5.5 Cardiovascular Disorders (Heart Failure)
5.6 Incontinence
5.7 Sleep Apnea
5.8 Respiratory Insufficiency (Diaphragm Pacing)
5.9 Other Disorders
Exhibit 5-1: Global Markets by Approach and Clinical Application, 2016-2022
Exhibit 5-2: Market for Technologies Targeting Neurological Disorders, 2016-2022
Exhibit 5-3: Global Market for Deep Brain Stimulation Technologies by Approach, 2016-2022
Exhibit 5-4: Global Deep Brain Stimulation Market, Estimated Supplier Shares, 2017
Exhibit 5-5: Global Market for Technologies Targeting Drug-Refractory Epilepsy by Approach, 2016-2022
Exhibit 5-6: Global Drug Refractory Epilepsy Neurostimulation Devices Market, Estimated Supplier Shares, 2017
Exhibit 5-7: Global Market for Technologies Targeting Major Depressive Disorders by Approach, 2016-2022
Exhibit 5-8: Global Major Depressive Disorder Neurostimulation Devices Market, Estimated Supplier Shares, 2017
Exhibit 5-9: Global Market for Technologies Targeting Migraine and Cluster Headache, 2016-2022
Exhibit 5-10: Global Migraine/Cluster Headache Noninvasive VNS Therapies Market, Estimated Supplier Shares, 2017
Exhibit 5-11: Global Market for Technologies Targeting Post-Stroke Mobility, 2016-2022
Exhibit 5-12: Global Post-Stroke Mobility Therapy Devices Market, Estimated Supplier Shares, 2017
Exhibit 5-13: Global Market for Technologies Targeting Hematological Disorders, 2016-2022
Exhibit 5-14: Global Market for Technologies Targeting Autoimmune Disorders, 2016-2022
Exhibit 5-15: Global Market for Technologies Targeting Chronic Widespread Pain, 2016-2022
Exhibit 5-16: Global Chronic Pain Market, Estimated Supplier Shares, 2017
Exhibit 5-17: Global Market for Technologies Targeting Heart Failure, 2016-2022
Exhibit 5-18: Global Heart Failure Market, Estimated Supplier Shares, 2017
Exhibit 5-19: Global Market for Technologies Targeting Incontinence, 2016-2022
Exhibit 5-20: Global Incontinence Market, Estimated Supplier Shares, 2017
Exhibit 5-21: Global Market for Technologies Targeting Sleep Apnea, 2016-2022
Exhibit 5-22: Global Sleep Apnea Market, Estimated Supplier Shares, 2017
Exhibit 5-23: Global Market for Diaphragm Pacing Technologies, 2016-2022
Exhibit 5-24: Global Diaphragm Pacing Market, Estimated Supplier Shares, 2017
Exhibit 5-25: Global Market for Other Neurostimulation Technologies, 2016-2022
6.0 MARKETS BY MAJOR GEOGRAPHY
6.1 United States
6.2 Major Europe
6.3 Major Asia
6.4 Rest of World
Exhibit 6-1: Global Market for Neurostimulation Technologies by Major Geography, 2016-2022
Exhibit 6-2: U.S. Market for Neurostimulation Technologies by Clinical Application, 2016-2022
Exhibit 6-3: Major Europe Market for Neurostimulation Technologies by Clinical Application, 2016-2022
Exhibit 6-4: Major Asia Market for Neurostimulation Technologies by Clinical Application, 2016-2022
Exhibit 6-5: Rest-of-World Market for Neurostimulation Technologies by Clinical Application, 2016-2022
7.0 COMPANY PROFILES
7.1 Abbott Laboratories (St. Jude Medical)
7.2 Aleva Neurotherapeutics
7.3 Alfred Mann Foundation
7.4 Atrotech Oy
7.5 Autonomic Technologies
7.6 Avery Biomedical
7.7 Axonics Modulation Technologies
7.8 BioControl Medical
7.9 BioElectronics Corporation
7.10 Bioinduction/Finetech Medical
7.11 Bioness
7.12 Bionic Enterprises
7.13 BlueWind Medical
7.14 Boston Scientific Corporation
7.15 BrainsWay
7.16 Burke Medical Research Institute
7.17 Cala Health
7.18 Cardionomic
7.19 Cephaly Technology (STX-Med)
7.20 Cerbomed GmbH
7.21 CerebralRx
7.22 Clinatec
7.23 Cogentix Medical
7.24 CorTec/Wyss Center
7.25 CVRx
7.26 Deep Brain Innovations
7.27 Defense Advanced Research Projects Agency
7.28 electroCore
7.29 Endonovo Therapeutics
7.30 EndoStim
7.31 eNeura
7.32 Enopace Medical
7.33 Feinstein Institute for Medical Research (Northwell Health)
7.34 FemPulse LLC
7.35 Functional Neuromodulation
7.36 Galvani Bioelectronics
7.37 Hanger
7.38 Hobart Group (Lavita, MetaCure, Renal Dynamics, Impulse Dynamics)
7.39 Innovative Health Solutions
7.40 Inspire Medical Systems
7.41 IntraPace
7.42 Laboratoire MXM (Axonic Neuromodulation Systems)
7.43 LivaNova (Cyberonics, ImThera)
7.44 MagVenture
7.45 Mainstay Medical
7.46 Medtronic
7.47 Micro Transponder
7.48 Neurolief
7.49 NeuroMetrix
7.50 Neuronetics
7.51 Neuronix
7.52 NeuroPace
7.53 NeuroSigma
7.54 Neuros Medical
7.55 NeuroTech International Ltd./AAT Research Ltd.
7.56 NeuroTronik
7.57 Nevro
7.58 Nexeon Medsystems/Nuviant Medical
7.59 Nuvectra
7.60 Ottobock
7.61 (Beijing) PINS Medical
7.62 ReShape Lifesciences (EnteroMedics)
7.63 Respicardia
7.64 Saluda Medical
7.65 Sanguistat
7.66 SceneRay
7.67 Scion NeuroStim
7.68 SetPoint Medical
7.69 SPR Therapeutics
7.70 Stimwave
7.71 Synapse Biomedical
7.72 Tal Medical
7.73 CHUs Jean Monnet &Saint Etienne/Life Medical Control/NBA Techno
7.74 University of California Berkeley